TRUFF — Red Light Holland Corp.
—
OTC ·
Unknown ·
Unknown ·
CIK 1836747 ·
Last close
$0.02
Market Cap
—
52W High
$0.04
52W Low
$0.00
ADV30
113,943
Next earnings
2026-11-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 186,070 | 169,737 | -1,402,319 | -1,866,594 | 21,861,244 | 2,597,788 | 3,823,877 |
| Mar 2026 | 875,322 | 458,573 | -787,508 | -2,527,999 | 14,569,516 | 8,471,343 | 3,349,190 |
| Dec 2025 | 1,264,798 | 357,920 | -1,197,457 | -1,378,899 | 18,199,952 | 9,237,626 | 3,583,397 |
| Sep 2025 | 754,084 | 327,294 | -996,236 | -1,166,695 | 19,018,028 | 10,226,236 | 3,405,796 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,421,528
Investing CF
$-1,226,324
Financing CF
$-766,029
CapEx
$-1,226,324
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.00
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-48,301,671
Inventory
$846,129
Receivables
$478,514
ST Investments
$581,578
EBIT TTM
$-7,112,186
Pretax Income TTM
$-7,170,661
Interest Exp TTM
$58,475
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,195,369 | -4,124,766 | -6,101,998 | 14,569,516 | 3,349,190 | 11,966,082 | -2,421,528 |
| Mar 2025 | 4,944,378 | -4,210,297 | -4,042,202 | 21,221,392 | 3,871,805 | 17,352,380 | -1,482,702 |
| Mar 2024 | 4,751,981 | -6,187,065 | -7,627,281 | 24,083,960 | 3,821,658 | 20,070,195 | -3,228,133 |
| Mar 2023 | 3,949,667 | -4,952,810 | -5,398,167 | 30,143,283 | 3,800,453 | 26,064,213 | -4,386,694 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRRN | Bryn Inc. | $945.00B | $2100.00 | — |
| KLAC | KLA CORP | $270.31B | $206.89 | — |
| TMO | THERMO FISHER SCIENTIFIC INC. | $242.11B | $654.80 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $209.76B | $222.64 | — |
| DHR | DANAHER CORP /DE/ | $150.48B | $214.06 | — |
News headlines (Yahoo Finance, 1h cache)
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Viol
2026-09-29 11:53 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista
2026-09-25 12:48 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
2026-09-22 11:33 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
2026-09-21 11:49 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
2026-09-17 11:52 · Yahoo
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness
2026-09-15 11:59 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
2026-09-14 11:53 · Yahoo
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
2026-09-10 11:55 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic
2026-09-08 11:52 · Yahoo
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
2026-09-03 11:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.